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We are incorporating these criteria into the management procedures of 
government agencies sponsoring primate research. 
The committee has also been concerned with the allocation of primate sup-
plies. In view of the uncertainties of current and future primate species, the time 
may soon be here when there will be insufficient numbers of one or more species 
to meet minimum health needs of the U.S. The plan provides an outline to be 
followed in such a situation. When such difficult choices have to be made, the 
priorities of distribution will be: 1) to fulfill legal requirements; 2) for use in 
breeding colonies; and 3) for other research and development purposes. 
Since the legal requirements are developed by government agencies as a 
result of their regulatory authority, the National Primate Plan recommends that 
any proposed federal guideline, standard, or regulation which either requires 
primate usage or restricts their availability be submitted to the committee to 
assess the potential impact on the overall national supply. We are also encourag-
ing users to reexamine their needs for acceptable alternatives as well as en-
couraging the development of new techniques and procedures that will further 
reduce their primate requirements. In addition, we are encouraging researchers 
to make the specifications for animals as rational and precise as possible. Finally, 
we must consider the ethical responsibilities shared by all of us who provide and 
use primates as research animals. Humane care issues, while not new, have 
become amplified in recent years. We must be prepared to deal with these issues 
which are surrounded by so much emotion. 
The biomedical community is searching for. alternatives to animal ex-
perimentation not only for humane, but also for economic reasons. Unfortunate-
ly, alternatives to testing the combined complex physiological systems found in 
the intact animal are currently quite limited, and to meet present needs can only 
be considered complementary or supplementary. However, such procedures may 
help to screen agents requiring testing and thus help to slow down the increasing 
requirements for animals. 
Conclusion 
In summary, a number of important steps have been taken to assure ade-
quate primate supplies. The research done with these animals is essential to pro-
vide knowledge of benefit to all people in all nations. A balanced program is 
needed worldwide that includes conservation of wild populations; improvement 
of wildlife management programs; better means of capture, conditioning, and 
shipping; increased domestic breeding of animals; and judicious use of these 
precious resources. 
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Scientific Issues and Regulation 
of Primate Use 
Andrew N. Rowan* 
Abstract 
Some of the patterns of use of nonhuman primates in the USA and Europe are 
outlined and a few specific examples of inappropriate and/or unnecessary use are 
described. The primate research resources program in the USA is examined and 
some suggestions as to how the program could be made more responsive to 
humane and conservation concerns are presented. 
The National Primate Plan (U.S. Dept. of Health, Education and Welfare, 
1980) opens with these words: "A severe and long-term shortage of nonhuman 
primates threatens the continuation of many essential health activities." It is cer-
tainly true that the supply of nonhuman primates has been disrupted over the 
past few years in India, Bangladesh and Malaysia. However, it is by no means 
clear that the continuation of essential health activities is threatened. 
The National Primate Plan specifically notes that the use of nonhuman 
primates in lifetime testing of steroid contraceptives is so critical that it is re-
quired with a force equivalent to that of law (Food and Drug Administration, 
1969). However, the steroid metabolic patterns of the primates used in this 
testing are sufficiently different (Shackleton and Mitchell, 1975) to prevent mean-
ingful extrapolation of results to human beings. Data gleaned from studies on 
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animals involving chronic administration of a new steroid contraceptive for 
several years are virtually useless for regulatory purposes. Therefore, in terms of 
health hazard evaluation for humans, these chronic tests are a waste of time, 
money and animals. 
Similarly, the National Primate Plan notes that between 5,000 and 6,000 
macaques are required annually for vaccine production and testing, mostly for 
poliomyelitis vaccine. This represents a considerable reduction over the late 
1950's when hundreds of thousands of rhesus macaques were used every year in 
the development and production of polio vaccines (LeCornu and Rowan, 1979). 
This reduction has occurred, in part, through the development of better methods 
of harvesting monkey kidney cells. In Denmark, for example, these methods have 
resulted in a reduction in the number of monkeys required from 400 to 40 (Fen-
nestad and Petersen, 1979). However, it is now technically possible to eliminate 
the present demand for macaques without jeopardizing human safety. 
Currently, two types of polio vaccine are produced: the live, attenuated 
(Sabin) vaccine and the inactivated (Salk) vaccine. The virus for both types can be 
grown in human cell culture although the yield from a given quantity of diploid 
human cells is lower than in early generation monkey cell cultures (Beale, 1979). 
Only small amounts of virus are needed for immunization with the Sabin vaccine 
(the virus grows in the vaccinee), but larger quantities of the Salk vaccine are re-
quired, thus making it more expensive than the Sabin. The price of the Salk vac-
cine could, however, be reduced by using cell-suspension cultures or microcar-
rier techniques to produce a larger virus yield from a given volume of culture 
fluid (Petricciani eta/, 1979). The technology is being developed and thus the 
economic need for monkey kidney cell cultures could possibly be eliminated. 
This would have health advantages since monkey kidney cell cultures are 
notorious for their contamination by extraneous agents, and up to 50% of 
monkey kidney ceil cultures may have to be discarded because of viral con-
tam in ants (Beale, 1979). 
Both vaccines are tested in several animal species, including monkeys. It is 
difficult to envisage a total replacement for monkeys in Sabin vaccine neurotox-
icity testing, but one could certainly eliminate the monkey test for the Salk vac-
cine. The cell culture test for live virus particles is more sensitive (safer?) than the 
monkey test (Beale, 1978) and the World Health Organi~ation (WHO) is consider-
ing a recommendation for a suitable cell culture test as a replacement method (F. 
Perkins, personal communication). Therefore, with a few technical modifications, 
and a change of attitude among regulators one could eliminate the need for 
monkeys to test the inactivated vaccine. However, memories of the Cutter 
disaster, when over 200 children contracted paralytic poliomyelitis after receiv-
ing an inadequately inactivated batch of Salk vaccine, still loom large in many 
minds despite our much greater understanding of the manufacturing process and 
our ability to guard against a repetition of such a disaster. 
Almost twenty percent of the projected U.S. demand for primates is ac-
counted for by the polio vaccine program. A switch from the Sabin to the Salk 
vaccine, the use of cell lines (human?) and microcarrier culture techniques, and 
dropping the requirement for the monkey test in Salk vaccine production could 
virtually eliminate this need. There are a few minor technical problems to be 
solved and much economic, political and bureaucratic inertia and resistance to 
overcome. Finally, it should be noted that there may still be some need for the 
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Sabin vaccine to deal with polio outbreaks since even Salk acknowledges that 
the Sabin vaccine is more effective under these circumstances (Boffey, 1977). The 
respective proponents of the Salk and Sabin vaccines are involved in a bitter 
argument over which is better in terms of effectiveness and safety (Editorial, 
1977; Salk and Salk, 1978). Where one has a well-disciplined community (as in 
Sweden), there is no doubt that the inactivated Salk vaccine is effective, but 
there are questions as to whether it can provide the same level of protection in 
Third World countries. The testing issue has also not yet been decided by the 
World Health Organization and even if the WHO does produce a new recommen-
dation, inertia will militate against authorities replacing the old monkey test. 
Nonetheless, it is clear that the use of nonhuman primates is not an essential re-
quirement for the production and testing of polio vaccine. 
While the use of monkeys in polio vaccine and oral contraceptive testing is a 
story of conflicting scientific data, conservative attitudes and inertia, the 
laboratory chimpanzee situation is a catalogue of mismanagement in which the 
chimpanzees come out a very distant last. In 1977, the National Institutes of 
Health (NIH) circulated a draft primate plan in which an annual need for 180 
chimpanzees was estimated (Interagency Primate Steering Committee, 1977). 
However, in 1978, the Interagency Primate Steering Committee (IPSC) published 
a report of a task force on chimpanzees which estimated a total annual demand 
of about 700 chimpanzees (Table 1). 
TABLE 1-IPSC Task Force Estimate of the Number of Chimpanzees Being 
Used in or Required for Biomedical Programs. 
Projected 
Field of Research Current Use Future Annual Demand 
Behavioral Sciences (not given) 50 
Infectious Diseases 
Hepatitis 156 314 
Other 46 46 
Neurological Diseases (not given) 45 
Hematology, immunology 
& immunogenetics 150 50 
Toxicology& pharmacology 200 100 
Reproductive biology 85 50 
Other (aging, aerospace, etc.) 25 80 
TOTALS 662+ 735 
Not only was this projection vastly inflated, but the reasons given for why 
the chimpanzees were so necessary were gross overstatements (Rowan, 1979). It 
is now commonly (if privately) accepted among laboratory primatologists that 
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economic need for monkey kidney cell cultures could possibly be eliminated. 
This would have health advantages since monkey kidney cell cultures are 
notorious for their contamination by extraneous agents, and up to 50% of 
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icity testing, but one could certainly eliminate the monkey test for the Salk vac-
cine. The cell culture test for live virus particles is more sensitive (safer?) than the 
monkey test (Beale, 1978) and the World Health Organi~ation (WHO) is consider-
ing a recommendation for a suitable cell culture test as a replacement method (F. 
Perkins, personal communication). Therefore, with a few technical modifications, 
and a change of attitude among regulators one could eliminate the need for 
monkeys to test the inactivated vaccine. However, memories of the Cutter 
disaster, when over 200 children contracted paralytic poliomyelitis after receiv-
ing an inadequately inactivated batch of Salk vaccine, still loom large in many 
minds despite our much greater understanding of the manufacturing process and 
our ability to guard against a repetition of such a disaster. 
Almost twenty percent of the projected U.S. demand for primates is ac-
counted for by the polio vaccine program. A switch from the Sabin to the Salk 
vaccine, the use of cell lines (human?) and microcarrier culture techniques, and 
dropping the requirement for the monkey test in Salk vaccine production could 
virtually eliminate this need. There are a few minor technical problems to be 
solved and much economic, political and bureaucratic inertia and resistance to 
overcome. Finally, it should be noted that there may still be some need for the 
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is now commonly (if privately) accepted among laboratory primatologists that 
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this report exaggerated the demand, presumably to make a case for additional 
importation from the wild as well as for more support for domestic breeding pro-
grams. There are currently 1100+ chimpanzees in laboratory and/or breeding 
facilities in the United States. These animals produce between fifty and seventy 
offspring annually, but a number of the infants die before reaching maturity. Lit-
tle concerted action is being taken to improve this state of affairs and, in fact, 
one of the most successful breeding colonies has been broken up (and may well 
be destroyed) as the result of inadequate coordination and bad planning by fund-
ing agencies. 
Several years ago, the Laboratory for Experimental Medicine and Surgery in 
Primates (LEMSIP) was awarded a contract for chimpanzee breeding for a 
hepatitis study program by the National Heart, Lung and Blood Institute (NHLBI). 
When the contract came up for renewal, it was put out for competitive bids and 
another three year contract awarded to the Southwest Foundation for Research 
and Education (SFRE). The stated reason for moving the contract was that SFRE 
had quoted a price that was half LEMSIP's projection of $1.1 million. This judg-
ment has been challenged, and New York University has sued NIH on the grounds 
that the issuing of the RFP (Request for Proposal) and review of the submissions 
had been mismanaged. Meanwhile, the chimpanzees still had to be moved. Over 
a period of two months, 73 animals were trucked from New York to Texas under 
conditions which, at best, could only be described as highly stressful. It is not par-
ticularly surprising that nine animals have subsequently died and that the 
breeding program has been totally disrupted. It is pertinent to note that LEMSIP's 
1978 breeding success rate of 35% (J. Moor-J ankowski, personal communication) 
was among the best (if not the best) in the country. 
This particular saga has been related in order to illustrate how the animals 
come off second best, especially when the situation is highly politicized, as in the 
LEMSIP-SFRE-NHLBI dispute. The chimpanzees were treated as chattel, to be 
picked up at a moment's notice and hauled thousands of miles across the United 
States without regard to anything more than mere survival. It was predicted that 
the move would disrupt the colony and that it would never achieve the stated 
goals of the contract, namely, ten offspring per annum. This prediction has, un-
fortunately, been borne out by subsequent events, and SFRE looks as if it will be 
hard-pressed to maintain the colony numbers, let alone increase the colony by 
thirty healthy offspring by june, 1982. However, NHLBI staff responsible for 
managing this contract have indicated that this does not concern them since they 
anticipate that they will no longer need a special chimpanzee colony after 
another year or two. It is not clear what will happen to the remaining animals 
when the contract expires. 
Apart from the problems surrounding the long-term maintenance of the col-
onies of great apes (and most are kept in facilities which are grossly inadequate 
considering the animals' social and psychological needs [d. McGrew, 1981]) 
there are other aspects of primate research in the United States which give cause 
for concern. It has been stated that the seven primate research centers around 
the country fail, with one or two exceptions, to provide adequate value for the 
money and top class research (NIH, 1976; Hobbs and Bleby, 1976). By contrast, 
LEMSIP, which, ironically, is on the verge of closing down, has been acknowl-
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edged to provide excellent value for the money (Hobbs and Bleby, 1976). One of 
the main problems is that the Primate Research Center (PRC) program has 
become a self-perpetuating oligarchy within the Animal Resources branch of 
NIH's Division of Research Resources. In 1975, the PRCs received $12.5 million 
for core support out of a total of $17.1 million allocated to laboratory animal 
resources. They have since maintained this dominant role within the funding pro-
gram. Because of the financial muscle behind the PRC program any efforts to 
reform the program have resulted in cosmetic changes rather than the necessary 
major overhaul. The Bolt, Beranek and Newman (BBN) consultant panel (NIH, 
1976) came out with some relatively hard-hitting proposals for reform, but a 
subsequent review of the PRC program (NIH, 1979), stimulated by the BBN 
report, either undercut many of the BBN proposals or was so general and vague 
as to be virtually useless. According to a member of the second review, the panel 
did not feel free to entertain any proposals which would have resulted in radical 
changes in the extent or scope of the primate center program (L. Rosenblum, per-
sonal communication). However, the panel did note that the quality of the scien-
tists in the PRCs was below par and that the centers do not have the reputation of 
being "the place to be." 
The undermining effect of the second review was most unfortunate since 
one of the BBN proposals could be developed to provide answers to many of the 
problems which currently plague the primate research effort. The BBN panel sug-
gested that a Primate Utilization Authority be established to oversee all primate 
breeding and use in the United States. This concept is, however, somewhat 
limited. It needs to be expanded to incorporate conservation questions and to in-
clude representation from humane and conservation groups. After all, the En-
dangered Species Scientific Authority has research community representation. 
Also, the name should be changed to the National Primate Study Authority 
(NPSA). There are other precedents for such an organization; for example, the Na-
tional Toxicology Program is essentially a consortium of federal agencies in-
volved in bioassays and the development of new methods. 
The NPSA should include adequate representation from user groups such as 
NIH and the Department of Defense, as well as from conservation and humane 
organizations. The NPSA should have oversight for the immediate primate 
breeding and research programs as well as for the long-term fate of the animals. 
It should look carefully at the proposed needs for primates and determine just 
how essential some of the research really is. For example, a European Economic 
Community task force (Committee on Medical and Public Health Research, 1979) 
identifies the essential primate research needs (Table 2) in a more limited manner 
than the National Primate Plan (Dept. of Health, Education and Welfare, 1980). In 
addition, greater attention needs to be focused on primate housing and on some 
of the research techniques, especially in behavioral studies. If a primate really is 
a good model of human behavior patterns (such as addiction, depression, anti-
social activity), then it presumably has very similar needs to humari beings which 
should be acknowledged and met. If it is not a good model of the human psyche 
then we should question whether such research should be done at all. 
For the great apes, we need to reassess our priorities completely. If the use 
of these animals is to be justified, then we consider that the following minimum 
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Community task force (Committee on Medical and Public Health Research, 1979) 
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than the National Primate Plan (Dept. of Health, Education and Welfare, 1980). In 
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social activity), then it presumably has very similar needs to humari beings which 
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conditions should be met: First, the animals should be kept under conditions 
which, as far as possible, meet their physical and social requirements. Second, 
breeding programs should be established to obviate any current or future impor-
tation from the wild. Third, the research project must not be terminal. Fourth, 
adequate provisions should be made for the lifetime of the animals being used, 
and it must be recognized that great apes cannot be moved around as though 
they were pieces of machinery. It must be stressed that these are mi~imal condi-
tions; ideally, we should accord the great apes the same quality of facilities and 
respect that we accord human subjects. 
In conclusion, we accept that there are some legitimate and essential uses of 
primates in biomedical programs, but we do not consider the present level 
necessary or the current controls adequate. The conservation and humane con-
cerns must be given adequate consideration and the primate program totally re-
evaluated. The Primate Research Centers currently receive over $16 million in 
core support. It is arguable that far better use could be made of all or a portion of 
this money if it were allocated to the development of other types of biomedical 
technology. The development of primate research models appears to have high 
prestige and yet there is no clear reason why it should. One can only speculate 
that such prestige stems from an anthropomorphic bias derived from the fact 
that primates are our close evolutionary relatives. If this is indeed the case, then 
we need to consider their interests much more closely. 
TABLE 2- Primate Use for Biomedical Research and Health Care(EEC, 1979)* 
Species 
Chimpanzee 
Macaque (Rhesus and 
Cynomolgus) 
New World Monkeys 
Baboon 
Research or Other Activity for which 
Availability of Primate Species is: 
Essential 
Hepatitis B (vaccine testing); 
Hepatitis "non-A-non-B." 
Production and testing of 
vaccines (mainly polio); Tox-
icology and teratology. 
Hepatitis A (marmosets); 
Hepatitis "non-A-non-B" 
(marmosets); DNA and RNA 
tumor viruses; Hematopoietic 
chimaerism (marmosets); 
Malaria (owl monkeys). 
Highly Desirable 
Hepatitis A; Certain cardio-
vascular diseases; Antifertility; 
Production of antisera. 
Reproductive physiology and anti-
fertility; Endocrinology; Diagnos-
tic virology; Immunology and 
transplantation. 
Teratology, reproductive 
physiology and antifertility; 
Cardiovascular diseases 
(mainly squirrel monkeys); 
Pharmacology and toxicology 
(mainly squirrel monkeys); 
Immunology and transplantation; 
Slow virus diseases. 
Cancer virology; Reproductive 
physiology. 
*From Reports and Memoranda of the Working Group on the Use and Supply of Non-human Primates 
for Biomedical Purposes. Committee on Medical Research Commission of the European Communities, 
Brussels, 1978. 
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conditions should be met: First, the animals should be kept under conditions 
which, as far as possible, meet their physical and social requirements. Second, 
breeding programs should be established to obviate any current or future impor-
tation from the wild. Third, the research project must not be terminal. Fourth, 
adequate provisions should be made for the lifetime of the animals being used, 
and it must be recognized that great apes cannot be moved around as though 
they were pieces of machinery. It must be stressed that these are mi~imal condi-
tions; ideally, we should accord the great apes the same quality of facilities and 
respect that we accord human subjects. 
In conclusion, we accept that there are some legitimate and essential uses of 
primates in biomedical programs, but we do not consider the present level 
necessary or the current controls adequate. The conservation and humane con-
cerns must be given adequate consideration and the primate program totally re-
evaluated. The Primate Research Centers currently receive over $16 million in 
core support. It is arguable that far better use could be made of all or a portion of 
this money if it were allocated to the development of other types of biomedical 
technology. The development of primate research models appears to have high 
prestige and yet there is no clear reason why it should. One can only speculate 
that such prestige stems from an anthropomorphic bias derived from the fact 
that primates are our close evolutionary relatives. If this is indeed the case, then 
we need to consider their interests much more closely. 
TABLE 2- Primate Use for Biomedical Research and Health Care(EEC, 1979)* 
Species 
Chimpanzee 
Macaque (Rhesus and 
Cynomolgus) 
New World Monkeys 
Baboon 
Research or Other Activity for which 
Availability of Primate Species is: 
Essential 
Hepatitis B (vaccine testing); 
Hepatitis "non-A-non-B." 
Production and testing of 
vaccines (mainly polio); Tox-
icology and teratology. 
Hepatitis A (marmosets); 
Hepatitis "non-A-non-B" 
(marmosets); DNA and RNA 
tumor viruses; Hematopoietic 
chimaerism (marmosets); 
Malaria (owl monkeys). 
Highly Desirable 
Hepatitis A; Certain cardio-
vascular diseases; Antifertility; 
Production of antisera. 
Reproductive physiology and anti-
fertility; Endocrinology; Diagnos-
tic virology; Immunology and 
transplantation. 
Teratology, reproductive 
physiology and antifertility; 
Cardiovascular diseases 
(mainly squirrel monkeys); 
Pharmacology and toxicology 
(mainly squirrel monkeys); 
Immunology and transplantation; 
Slow virus diseases. 
Cancer virology; Reproductive 
physiology. 
*From Reports and Memoranda of the Working Group on the Use and Supply of Non-human Primates 
for Biomedical Purposes. Committee on Medical Research Commission of the European Communities, 
Brussels, 1978. 
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